or Try an Advanced Search...

    Technical Analysis for APGE - Apogee Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 47.13 2.77% 1.27
    APGE closed up 2.77 percent on Friday, April 26, 2024, on 30 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong N/A Down Down
    Historical APGE trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Wide Bands Range Expansion 2.77%
    Gapped Down Weakness 2.77%
    Oversold Stochastic Weakness 2.77%
    Multiple of Ten Bearish Other 1.27%
    Wide Bands Range Expansion 1.27%
    Oversold Stochastic Weakness 1.27%
    NR7 Range Contraction -5.30%
    Narrow Range Bar Range Contraction -5.30%
    Older End-of-Day Signals for APGE ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 14 hours ago
    Up 3% about 14 hours ago
    Up 2% about 14 hours ago
    60 Minute Opening Range Breakout about 14 hours ago
    Up 1% about 14 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    APGE Chart by TradingView
    Basic chart:

    Profile

    Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Immunology Antibodies Monoclonal Antibodies Occupational Safety And Health Chronic Obstructive Pulmonary Disease Atopic Dermatitis Dermatitis Inflammatory Monoclonal Antibody Therapy Copd

    Is APGE a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 16 With 54% institutional ownership, Apogee Therapeutics, Inc. (NASDAQ:APGE) is a favorite amongst the big guns
    Apr 3 Paragon’s hub-and-spoke biotech model yields another reverse merger
    Mar 28 Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
    Mar 25 Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
    Mar 12 Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
    Mar 8 Apogee Therapeutics stock slides on pricing upsized stock offering to raise $420 million
    Mar 7 Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
    Mar 6 Apogee Therapeutics: Success In Phase 1 Bodes Well For Continued APG777 Advancement
    Mar 6 Apogee Highlights Corporate reports FY results
    Mar 6 Insiders Of Apogee Therapeutics Reap Rewards After Their Investment Jumps Another US$74m
    See more APGE news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 72.29
    52 Week Low 14.22
    Average Volume 783,271
    200-Day Moving Average 0.00
    50-Day Moving Average 53.85
    20-Day Moving Average 53.30
    10-Day Moving Average 48.84
    Average True Range 3.90
    RSI (14) 39.39
    ADX 32.06
    +DI 12.92
    -DI 28.30
    Chandelier Exit (Long, 3 ATRs) 57.70
    Chandelier Exit (Short, 3 ATRs) 55.30
    Upper Bollinger Bands 63.86
    Lower Bollinger Band 42.75
    Percent B (%b) 0.21
    BandWidth 39.61
    MACD Line -2.87
    MACD Signal Line -1.79
    MACD Histogram -1.0814
    Fundamentals Value
    Market Cap 2.26 Billion
    Num Shares 48 Million
    EPS
    Price-to-Sales 0.00
    Price-to-Book 0.00
    Dividend 0.00
    Dividend Yield 0.00%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 51.55
    Resistance 3 (R3) 51.17 49.32 50.81
    Resistance 2 (R2) 49.32 48.19 49.51 50.57
    Resistance 1 (R1) 48.22 47.50 48.77 48.60 50.32
    Pivot Point 46.37 46.37 46.65 46.56 46.37
    Support 1 (S1) 45.28 45.25 45.83 45.66 43.94
    Support 2 (S2) 43.43 44.55 43.62 43.69
    Support 3 (S3) 42.33 43.43 43.45
    Support 4 (S4) 42.71